A
2.63
0.59 (28.92%)
| 前收盘价格 | 2.04 |
| 收盘价格 | 2.10 |
| 成交量 | 50,299 |
| 平均成交量 (3个月) | 70,731 |
| 市值 | 74,225,968 |
| 价格/销量 (P/S) | 8.96 |
| 股市价格/股市净资产 (P/B) | 6.27 |
| 52周波幅 | |
| 利润日期 | 9 Nov 2022 |
| 营业毛利率 | -60.90% |
| 营业利益率 (TTM) | -50.68% |
| 稀释每股收益 (EPS TTM) | -0.460 |
| 季度收入增长率 (YOY) | 5.40% |
| 总债务/股东权益 (D/E MRQ) | 37.33% |
| 流动比率 (MRQ) | 5.64 |
| 营业现金流 (OCF TTM) | -9.94 M |
| 杠杆自由现金流 (LFCF TTM) | -2.06 M |
| 资产报酬率 (ROA TTM) | -12.26% |
| 股东权益报酬率 (ROE TTM) | -28.76% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | Alpha Teknova, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
1.5
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.50 |
|
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 10.95% |
| 机构持股比例 | 82.17% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合